Awakn Life Sciences (TSE:AWKN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Awakn Life Sciences has partnered with the University of Nottingham to conduct preclinical trials on a new chemical entity aimed at enhancing mental health treatments. The study, led by Dr. Madeleine King, focuses on the potential of aminoindane to improve social cognition and behaviors, particularly for PTSD. This collaboration marks a significant step in Awakn’s mission to develop innovative therapies for mental health disorders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
